Mortality Due to Acute Respiratory Distress Syndrome in Latin America.

OBJECTIVES: Mortality due to acute respiratory distress syndrome (ARDS) is a major global health problem. Knowledge of epidemiological data on ARDS is crucial to design management, treatment strategies, and optimize resources. There is ample data regarding mortality of ARDS from high-income countries; in this review, we evaluated mortality due to ARDS in Latin America. DATA SOURCES: We searched in PubMed, Cochrane Central Register of Controlled Trials, Web of Science, and Latin American and Caribbean Health Science Literature databases from 1967 to March 2023. STUDY SELECTION: We searched prospective or retrospective observational studies and randomized controlled trials conducted in Latin American countries reporting ARDS mortality. DATA EXTRACTION: Three pairs of independent reviewers checked all studies for eligibility based on their titles and abstracts. We performed meta-analysis of proportions using a random-effects model. We performed sensitivity analyses including studies with low risk of bias and with diagnosis using the Berlin definition. Subgroup analysis comparing different study designs, time of publication (up to 2000 and from 2001 to present), and studies in which the diagnosis of ARDS was made using Pa o2 /F io2 less than or equal to 200 and regional variations. Subsequently, we performed meta-regression analyses. Finally, we graded the certainty of the evidence (Grading of Recommendations Assessment, Development, and Evaluation). DATA SYNTHESIS: Of 3315 articles identified, 32 were included (3627 patients). Mortality was 52% in the pooled group (low certainty of evidence). In the sensitivity analysis (according to the Berlin definition), mortality was 46% (moderate certainty of evidence). In the subgroup analysis mortality was 53% (randomized controlled trials), 51% (observational studies), 66% (studies published up to 2000), 50% (studies after 2000), 44% (studies with Pa o2 /F io2 ≤ 200), 56% (studies from Argentina/Brazil), and 40% (others countries). No variables were associated with mortality in the meta-regression. CONCLUSIONS: ARDS mortality in Latin America remains high, as in other regions. These results should constitute the basis for action planning to improve the prognosis of patients with ARDS (PROSPERO [CRD42022354035]).

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial.

BACKGROUND: We aimed to evaluate icatibant, a competitive antagonist of the bradykinin B2 receptors, for the treatment of inpatients with coronavirus disease 2019 (COVID-19) pneumonia admitted in the early hypoxemic stage. METHODS: The randomized, open-label clinical trial of icatibant for COVID-19 pneumonia (ICAT·COVID, registered as NCT04978051 at ClinicalTrials.gov) was conducted in Barcelona. Inpatients requiring supplemental but not high-flow oxygen or mechanical ventilation were allocated (1:1) to treatment with either three 30-mg icatibant doses/d for 3 consecutive days plus standard care or standard care alone, and followed for up to 28 days after initial discharge. The primary and key secondary outcomes were clinical response on study day 10/discharge and clinical efficacy at 28 days from initial discharge, respectively. RESULTS: Clinical response occurred in 27 of 37 patients (73.0%) in the icatibant group and 20 of 36 patients (55.6%) in the control group (rate difference, 17.42; 95% confidence interval [CI], -4.22 to 39.06; P = .115). Clinical efficacy ensued in 37 patients (100.0%) in the icatibant group and 30 patients (83.3%) in the control group (rate difference, 16.67; 95% CI, 4.49-28.84; P = .011). No patient died in the icatibant group, compared with 6 patients (16.7%) in the control group (P = .011). All patients but 1 had adverse events, which were evenly distributed between study arms. No patient withdrew because of adverse events. CONCLUSIONS: Adding icatibant to standard care was safe and improved both COVID-19 pneumonia and mortality in this proof-of-concept study. A larger, phase 3 trial is warranted to establish the clinical value of this treatment. CLINICAL TRIALS REGISTRATION: NCT04978051.

Age-dependent nasal immune responses in non-hospitalized bronchiolitis children.

Bronchiolitis in children is associated with significant rates of morbidity and mortality. Many studies have been performed using samples from hospitalized bronchiolitis patients, but little is known about the immunological responses from infants suffering from mild/moderate bronchiolitis that do not require hospitalization. We have studied a collection of nasal lavage fluid (NLF) samples from outpatient bronchiolitis children as a novel strategy to unravel local humoral and cellular responses, which are not fully characterized. The children were age-stratified in three groups, two of them (GI under 2-months, GII between 2-4 months) presenting a first episode of bronchiolitis, and GIII (between 4 months and 2 years) with recurrent respiratory infections. Here we show that elevated levels of pro-inflammatory cytokines (IL1ß, IL6, TNFα, IL18, IL23), regulatory cytokines (IL10, IL17A) and IFNγ were found in the three bronchiolitis cohorts. However, little or no change was observed for IL33 and MCP1, at difference to previous results from bronchiolitis hospitalized patients. Furthermore, our results show a tendency to IL1ß, IL6, IL18 and TNFα increased levels in children with mild pattern of symptom severity and in those in which non RSV respiratory virus were detected compared to RSV+ samples. By contrast, no such differences were found based on gender distribution. Bronchiolitis NLFs contained more IgM, IgG1, IgG3 IgG4 and IgA than NLF from their age-matched healthy controls. NLF from bronchiolitis children predominantly contained neutrophils, and also low frequency of monocytes and few CD4+ and CD8+ T cells. NLF from infants older than 4-months contained more intermediate monocytes and B cell subsets, including naïve and memory cells. BCR repertoire analysis of NLF samples showed a biased VH1 usage in IgM repertoires, with low levels of somatic hypermutation. Strikingly, algorithmic studies of the mutation profiles, denoted antigenic selection on IgA-NLF repertoires. Our results support the use of NLF samples to analyze immune responses and may have therapeutic implications.

Validation of a non-laboratorial questionnaire to identify Metabolic Syndrome among a population in central Mexico.

OBJECTIVE: To determine the reliability of a non-laboratorial questionnaire, the Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (ESF-I) for identifying Metabolic Syndrome among a population in central Mexico. METHODS: Clinical and biochemical parameters were collected for 232 participants from 1 June 2012 - 31 August 2013. Three definitions of Metabolic Syndrome (Harmonizing, National Cholesterol Education Program Expert Panel and Adult Treatment Panel III [ATPIII], and International Diabetes Federation [IDF]) were used to allocate subjects to either the normal or Metabolic Syndrome positive (MetS+) group. The predictability of the questionnaire was determined by the Area-Under-the-Receiver-Operating Characteristic curve (AUC). Youden's index was calculated and the highest score was considered the optimal cutoff value. Cohen´s kappa (κ) was calculated to determine the level of agreement between the ESF-I questionnaire (max score: 15 based on 15 items) and Metabolic Syndrome. RESULTS: From 53.8% - 60.7% of the participants were determined to be MetS+. The average questionnaire score was significantly higher in the MetS+ group for each definition (4.0 vs. 8.0, P < 0.05). The ESF-I questionnaire was predictive for the Harmonizing definition (AUC = 0.841, 95%CI: 0.790 - 0.892), the ATPIII definition (AUC = 0.827, 95%CI: 0.774 - 0.880), and the IDF definition (AUC = 0.836, 95%CI: 0.785 - 0.887). A cutoff value of 7 was determined for each definition; therefore, the cohort was re-categorized based on questionnaire results. There was a strong agreement between the ESF-I questionnaire and MetS (Harmonizing: accuracy = 77.6%, κ = 0.554; ATPIII: accuracy = 74.1%, κ = 0.489; IDF: accuracy = 74.6%, κ = 0.495, P < 0.001). CONCLUSION: The ESF-I questionnaire can identify MetS+ patients, and therefore, lead to earlier diagnoses, reduced number of consultations, and lower costs with easier application.

Hyperreactio luteinalis and hypothyroidism: A case report.

We report a case of hyperreactio luteinalis (HL) and hypothyroidism diagnosed at 13 weeks of pregnancy. A 29-year-old woman with a spontaneous 13-week singleton pregnancy presented with hirsutism and a pelvic mass. Ultrasound showed a viable pregnancy compatible with the gestational age and multiple cystic lesions on both ovaries. Her TSH levels were markedly elevated and diagnostic of hypothyroidism, for which she was treated. Two days after presentation, she had a spontaneous abortion. The products of conception were histologically normal. Follow-up at 3 months showed resolution of the ovarian cysts, and the previously elevated androgen levels were in the normal range. Hyperreactio luteinalis was diagnosed. Her elevated TSH levels may have contributed to hyperreactio luteinalis through the activation of the hCG receptor.

Validation of a non-laboratorial questionnaire to identify Metabolic Syndrome among a population in central Mexico

[ABSTRACT]. Objective. To determine the reliability of a non-laboratorial questionnaire, the Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (ESF-I) for identifying Metabolic Syndrome among a population in central Mexico. Methods. Clinical and biochemical parameters were collected for 232 participants from 1 June 2012 – 31 August 2013. Three definitions of Metabolic Syndrome (Harmonizing, National Cholesterol Education Program Expert Panel and Adult Treatment Panel III [ATPIII], and International Diabetes Federation [IDF]) were used to allocate subjects to either the normal or Metabolic Syndrome positive (MetS+) group. The predictability of the questionnaire was determined by the Area-Under-the-Receiver-Operating Characteristic curve (AUC). Youden’s index was calculated and the highest score was considered the optimal cutoff value. Cohen´s kappa (κ ) was calculated to determine the level of agreement between the ESF-I questionnaire (max score: 15 based on 15 items) and Metabolic Syndrome. Results. From 53.8% – 60.7% of the participants were determined to be MetS+. The average questionnaire score was significantly higher in the MetS+ group for each definition (4.0 vs. 8.0, P < 0.05). The ESF-I questionnaire was predictive for the Harmonizing definition (AUC = 0.841, 95%CI: 0.790 – 0.892), the ATPIII definition (AUC = 0.827, 95%CI: 0.774 – 0.880), and the IDF definition (AUC = 0.836, 95%CI: 0.785 – 0.887). A cutoff value of 7 was determined for each definition; therefore, the cohort was re-categorized based on questionnaire results. There was a strong agreement between the ESF-I questionnaire and MetS (Harmonizing: accuracy = 77.6%, κ = 0.554; ATPIII: accuracy = 74.1%, κ = 0.489; IDF: accuracy = 74.6%, κ = 0.495, P < 0.001). Conclusion. The ESF-I questionnaire can identify MetS+ patients, and therefore, lead to earlier diagnoses, reduced number of consultations, and lower costs with easier application.

[RESUMEN]. Objetivo. Determinar la fiabilidad de un cuestionario en el que no se recurre al diagnóstico de laboratorio, la Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (ESF-I), para detectar el síndrome metabólico en una población de la región central de México. Métodos. Se recogieron parámetros clínicos y bioquímicos de 232 participantes desde el 1 de junio del 2012 al 31 de agosto del 2013. Se usaron tres definiciones de síndrome metabólico (la unificadora, la del Grupo de Expertos en el Tratamiento de Adultos [ATPIII] del Programa Nacional de Educación sobre el Colesterol y la de la Federación Internacional de la Diabetes [FID]) para asignar los participantes al grupo normal o al grupo de síndrome metabólico positivo (SMet+). Se determinó la previsibilidad del cuestionario con el área bajo la curva de eficacia diagnóstica (curva ROC). Se calculó el índice de Youden y la puntuación más alta se consideró el valor de corte óptimo. El coeficiente (k) de Cohen se calculó para determinar el grade de acuerdo entre el cuestionario ESF-I (máxima puntuación: 15 sobre 15 ítems) y el síndrome metabólico. Resultados. Del 53,8 % al 60,7 % de los participantes se asignaron al grupo SMet+. La puntuación promedio del cuestionario fue significativamente mayor en el grupo de SMet+ para cada definición (4,0 vs. 8.0, P < 0.05). El cuestionario ESF-I fue predictivo para la definición unificadora (AUC = 0,841, 95 % CI: 0,790 – 0,892), la definición ATPIII (AUC = 0,827, 95 % CI: 0,774 – 0,880) y la definición de la FID (AUC = 0,836, 95 % CI: 0,785 – 0,887). Se determinó un el valor de corte óptimo de 7 para cada definición; por lo tanto, se reclasificó la cohorte según los resultados del cuestionario. Hubo una gran coincidencia entre el cuestionario ESF-I y SMet (unificadora: exactitud = 77,6 %, k = 0,554; ATPIII: exactitud = 74,1 %, k = 0,489; FID: exactitud = 74,6%, k = 0,495, P < 0,001). Conclusiones. El cuestionario ESF-I puede detectar pacientes con SMet+ y, por lo tanto, conducir a diagnósticos más tempranos, reducir la cantidad de consultas y reducir los costos con una aplicación más fácil.

[RESUMO]. Objetivo. Determinar a confiabilidade de um instrumento de coleta de dados não laboratoriais, Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (pesquisa de identificação de indivíduos com comprometimento metabólico em fase I, ESF-I) para identificar síndrome metabólica em uma população da região central do México. Métodos. Foram coletados parâmetros clínicos e bioquímicos de 232 participantes da pesquisa entre 1o de junho de 2012 e 31 de agosto de 2013. O estudo se baseou em três definições de síndrome metabólica (definição harmonizada do Painel de Especialistas do Programa Nacional de Educação em Colesterol dos Estados Unidos [NCEP]; Painel para Tratamento de Adultos III [ATPIII]; e Federação Internacional de Diabetes [FIL]) para alocar os participantes em um grupo normal ou em um grupo com síndrome metabólica (SM). A previsibilidade do instrumento foi determinada pela área sob a curva ROC (característica de operação do receptor) (AUC). O índice de Youden foi calculado e o escore mais alto foi considerado o valor ideal de corte. O coeficiente kappa de Cohen (k) foi calculado para determinar o grau de concordância entre o questionário ESF-1 (pontuação máxima de 15 em 15 itens) e a síndrome metabólica. Resultados. Foi determinado que 53,8% a 60,7% dos participantes apresentavam SM. A pontuação média no instrumento foi significativamente maior no grupo SM com cada uma das definições usadas (4,0 vs. 8,0, P<0,05). O questionário ESF-I foi preditivo com a definição harmonizada (AUC 0,841; IC 95% 0,790–0,892), com a definição do ATPIII (AUC 0,827; IC 95% 0,774–0,880) e com a definição da FIL (AUC 0,836; IC 95% 0,785–0,887). Um valor de corte de 7 foi determinado para cada definição e a coorte foi recategorizada de acordo com os resultados do instrumento. Foi observada uma forte concordância entre o questionário ESF-I e o grupo SM (harmonizada: precisão = 77,6%, k = 0,554; ATPIII: precisão = 74,1%, k = 0,489; FIL: precisão = 74,6%, k = 0,495, P<0,001). Conclusão. O questionário ESF-I é capaz de identificar pacientes com síndrome metabólica, possibilitando o diagnóstico precoce, um número menor de consultas e um custo menor com uma aplicação mais simples.

Validation of a non-laboratorial questionnaire to identify Metabolic Syndrome among a population in central Mexico / Validación de un cuestionario en el que no se recurre al diagnóstico de laboratorio para detectar el síndrome metabólico en una población de la zona central de México / Validação de um instrumento de coleta de dados não laboratoriais para identificar síndrome metabólica em uma população da região central do México

ABSTRACT Objective To determine the reliability of a non-laboratorial questionnaire, the Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (ESF-I) for identifying Metabolic Syndrome among a population in central Mexico. Methods Clinical and biochemical parameters were collected for 232 participants from 1 June 2012 - 31 August 2013. Three definitions of Metabolic Syndrome (Harmonizing, National Cholesterol Education Program Expert Panel and Adult Treatment Panel III [ATPIII], and International Diabetes Federation [IDF]) were used to allocate subjects to either the normal or Metabolic Syndrome positive (MetS+) group. The predictability of the questionnaire was determined by the Area-Under-the-Receiver-Operating Characteristic curve (AUC). Youden's index was calculated and the highest score was considered the optimal cutoff value. Cohen´s kappa (κ) was calculated to determine the level of agreement between the ESF-I questionnaire (max score: 15 based on 15 items) and Metabolic Syndrome. Results From 53.8% - 60.7% of the participants were determined to be MetS+. The average questionnaire score was significantly higher in the MetS+ group for each definition (4.0 vs. 8.0, P < 0.05). The ESF-I questionnaire was predictive for the Harmonizing definition (AUC = 0.841, 95%CI: 0.790 - 0.892), the ATPIII definition (AUC = 0.827, 95%CI: 0.774 - 0.880), and the IDF definition (AUC = 0.836, 95%CI: 0.785 - 0.887). A cutoff value of 7 was determined for each definition; therefore, the cohort was re-categorized based on questionnaire results. There was a strong agreement between the ESF-I questionnaire and MetS (Harmonizing: accuracy = 77.6%, κ = 0.554; ATPIII: accuracy = 74.1%, κ = 0.489; IDF: accuracy = 74.6%, κ = 0.495, P < 0.001). Conclusion The ESF-I questionnaire can identify MetS+ patients, and therefore, lead to earlier diagnoses, reduced number of consultations, and lower costs with easier application.

RESUMEN Objetivo Determinar la fiabilidad de un cuestionario en el que no se recurre al diagnóstico de laboratorio, la Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (ESF-I), para detectar el síndrome metabólico en una población de la región central de México. Métodos Se recogieron parámetros clínicos y bioquímicos de 232 participantes desde el 1 de junio del 2012 al 31 de agosto del 2013. Se usaron tres definiciones de síndrome metabólico (la unificadora, la del Grupo de Expertos en el Tratamiento de Adultos [ATPIII] del Programa Nacional de Educación sobre el Colesterol y la de la Federación Internacional de la Diabetes [FID]) para asignar los participantes al grupo normal o al grupo de síndrome metabólico positivo (SMet+). Se determinó la previsibilidad del cuestionario con el área bajo la curva de eficacia diagnóstica (curva ROC). Se calculó el índice de Youden y la puntuación más alta se consideró el valor de corte óptimo. El coeficiente (k) de Cohen se calculó para determinar el grade de acuerdo entre el cuestionario ESF-I (máxima puntuación: 15 sobre 15 ítems) y el síndrome metabólico. Resultados Del 53,8 % al 60,7 % de los participantes se asignaron al grupo SMet+. La puntuación promedio del cuestionario fue significativamente mayor en el grupo de SMet+ para cada definición (4,0 vs. 8.0, P < 0.05). El cuestionario ESF-I fue predictivo para la definición unificadora (AUC = 0,841, 95 % CI: 0,790 - 0,892), la definición ATPIII (AUC = 0,827, 95 % CI: 0,774 - 0,880) y la definición de la FID (AUC = 0,836, 95 % CI: 0,785 - 0,887). Se determinó un el valor de corte óptimo de 7 para cada definición; por lo tanto, se reclasificó la cohorte según los resultados del cuestionario. Hubo una gran coincidencia entre el cuestionario ESF-I y SMet (unificadora: exactitud = 77,6 %, κ = 0,554; ATPIII: exactitud = 74,1 %, κ = 0,489; FID: exactitud = 74,6%, κ = 0,495, P < 0,001). Conclusiones El cuestionario ESF-I puede detectar pacientes con SMet+ y, por lo tanto, conducir a diagnósticos más tempranos, reducir la cantidad de consultas y reducir los costos con una aplicación más fácil.

RESUMO Objetivo Determinar a confiabilidade de um instrumento de coleta de dados não laboratoriais, Encuesta de Identificación de Sujetos Metabólicamente Comprometidos en Fase-I (pesquisa de identificação de indivíduos com comprometimento metabólico em fase I, ESF-I) para identificar síndrome metabólica em uma população da região central do México. Métodos Foram coletados parâmetros clínicos e bioquímicos de 232 participantes da pesquisa entre 1° de junho de 2012 e 31 de agosto de 2013. O estudo se baseou em três definições de síndrome metabólica (definição harmonizada do Painel de Especialistas do Programa Nacional de Educação em Colesterol dos Estados Unidos [NCEP]; Painel para Tratamento de Adultos III [ATPIII]; e Federação Internacional de Diabetes [FIL]) para alocar os participantes em um grupo normal ou em um grupo com síndrome metabólica (SM). A previsibilidade do instrumento foi determinada pela área sob a curva ROC (característica de operação do receptor) (AUC). O índice de Youden foi calculado e o escore mais alto foi considerado o valor ideal de corte. O coeficiente kappa de Cohen (κ) foi calculado para determinar o grau de concordância entre o questionário ESF-1 (pontuação máxima de 15 em 15 itens) e a síndrome metabólica. Resultados Foi determinado que 53,8% a 60,7% dos participantes apresentavam SM. A pontuação média no instrumento foi significativamente maior no grupo SM com cada uma das definições usadas (4,0 vs. 8,0, P<0,05). O questionário ESF-I foi preditivo com a definição harmonizada (AUC 0,841; IC 95% 0,790-0,892), com a definição do ATPIII (AUC 0,827; IC 95% 0,774-0,880) e com a definição da FIL (AUC 0,836; IC 95% 0,785-0,887). Um valor de corte de 7 foi determinado para cada definição e a coorte foi recategorizada de acordo com os resultados do instrumento. Foi observada uma forte concordância entre o questionário ESF-I e o grupo SM (harmonizada: precisão = 77,6%, κ = 0,554; ATPIII: precisão = 74,1%, κ = 0,489; FIL: precisão = 74,6%, κ = 0,495, P<0,001). Conclusão O questionário ESF-I é capaz de identificar pacientes com síndrome metabólica, possibilitando o diagnóstico precoce, um número menor de consultas e um custo menor com uma aplicação mais simples.

Transición parasitaria: experiencia en un hospital pediátrico de tercer nivel (1990-2010) / Parasitological transition: Experience in a third-level pediatric hospital (1990-2010)

ResumenINTRODUCCIÓN: Hace algunos años, el motivo principal para la solicitud del diagnóstico parasitológico era la sospecha de una etiología de base parasitaria. En la actualidad, el motivo de consulta y la solicitud del diagnóstico se encuentran asociados con una comorbilidad hemato-oncológica, autoinmune, inmunodeficiente o una condición postrasplante.MÉTODO: Se analizaron los resultados del laboratorio de parasitología clínica del Hospital Infantil de México Federico Gómez de enero de 1990 a diciembre del 2010, para obtener la frecuencia y distribución de parásitos y comensales por año y década.RESULTADOS: Se analizaron 211,600 muestras del periodo estudiado, con una media anual de 10,100 y desviación estándar de 3,500. El porcentaje de parásitos y comensales fue del 37.73%, y la frecuencia de positividad solo a parásitos fue del 21.4%. La diferencia de proporciones entre décadas resultó significativa, con una p < 0.0001.CONCLUSIONES: La tendencia en el comportamiento de las parasitosis intestinales durante el periodo estudiado mostró un cambio tanto en frecuencia como en género y especie de los agentes reportados. La generación de información de carácter epidemiológico es necesaria para conocer la tendencia de las parasitosis y de sus variaciones a través del tiempo.

AbstractBACKGROUND: In recent years, the main reason for parasitological diagnosis was suspicion of a parasitic etiology. Currently, diagnosis and consultation are associated with co-morbidity with a hemato-oncological, autoimmune, immunodeficiency or post-transplant condition.METHODS: Results collected from the Parasitology Laboratory of the Hospital Infantil de Mexico Federico Gómez from January 1990 to December 2010 were analyzed to determine the frequency and distribution of parasites and commensals per year and decade.RESULTS: There were 211,600 samples analyzed with a statistical media of 10,100 and a standard deviation of 3,500 samples. Percentage of observations for parasitic structures as well as commensals was 37.73% according to Pearson Chi square with a significant difference among percentages between decades (p < 0.0001).CONCLUSIONS: Behavioral tendency of intestinal parasitosis during the last two decades shows a change in frequency and genera from the agents that were reported at this pediatric health care level. The processing of epidemiologic information is important in order to determine the response of the parasitosis and its variations over time.

[Parasitological transition: Experience in a third-level pediatric hospital (1990-2010)]. / Transición parasitaria: experiencia en un hospital pediátrico de tercer nivel (1990-2010).

BACKGROUND: In recent years, the main reason for parasitological diagnosis was suspicion of a parasitic etiology. Currently, diagnosis and consultation are associated with co-morbidity with a hemato-oncological, autoimmune, immunodeficiency or post-transplant condition. METHODS: Results collected from the Parasitology Laboratory of the Hospital Infantil de Mexico Federico Gómez from January 1990 to December 2010 were analyzed to determine the frequency and distribution of parasites and commensals per year and decade. RESULTS: There were 211,600 samples analyzed with a statistical media of 10,100 and a standard deviation of 3,500 samples. Percentage of observations for parasitic structures as well as commensals was 37.73% according to Pearson Chi square with a significant difference among percentages between decades (p<0.0001). CONCLUSIONS: Behavioral tendency of intestinal parasitosis during the last two decades shows a change in frequency and genera from the agents that were reported at this pediatric health care level. The processing of epidemiologic information is important in order to determine the response of the parasitosis and its variations over time.

Oral health status in 12 to 17-year-old school children from Valle Nonguén, Concepción, 2013 / Estado de salud bucal en escolares de 12 a 17 años de Valle Nonguén, Concepción, 2013

Dental caries, periodontal disease and dento-maxillary anomalies are the most common oral problems both globally and nationally. The aim of this study is to determine the oral health status in terms of caries damage, oral hygiene and dento-maxillary anomalies, and their relationship with socio-demographic factors in school children from Valle Nonguén sector, whose ages fluctuate from 12 to 17 years old. This is a study of prevalence which was conducted on a sample of 210 school children, the following indexes were utilized: DMFT, Simplified Oral Hygiene Index (OHI-S), and Dental Aesthetic Index (DAI), sex, age and type of educational establishment (public/subsidized). The results showed that 94.76 percent of the students have caries damage with a DMFT average of 6.87+/-3.42, higher in women and adolescents aged 16-17; 73.57 percent of them have a regular hygiene, with OHI-S higher in 14-15-year-old adolescents and public schools, and a 75.2 percent has at least one manifest malocclusion (19.05 percent in a disabling level). These results show that the 12-17-year-old students from Valle Nonguén have a high rate of oral disease in all indexes, higher than national and international studies. A priority is to design and implement preventive/healing dental programs in this group. These results question the design and possible impact of the new program "FONASA Libre Elección 12-17 años" in neighborhoods with limited resources and high treatment needs.

La caries dental, la enfermedad periodontal y las anomalías dento-maxilares son los problemas bucales más frecuentes tanto a nivel mundial como nacional. El objetivo de este trabajo es determinar el estado de salud bucal en cuanto a historia de caries, higiene oral y anomalías dento-maxilares, y su relación con características socio-demográficas en escolares de 12 a 17 años del sector Valle Nonguén. Estudio de prevalencia sobre una muestra de 210 escolares, se utilizaron los siguientes indicadores: COPD, índice de higiene oral simplificado(IHO-S), índice de estética dental (IED), sexo, edad y tipo de colegio (municipal/subvencionado). Los resultados mostraron que: 94,76 por ciento de los escolares presenta historia de caries con COPD promedio de 6,87+/-3,42, mayor en mujeres y adolescentes de 16-17 años; 73,57 por ciento tiene una higiene regular, con un IHO-S mayor en 14-15 años y adolescentes de colegios municipales; y el 75,2 por ciento presenta al menos una maloclusión manifiesta (19,05 por ciento de carácter discapacitante).Estos resultados muestran que los escolares de 12 a 17 años del sector Valle Nonguén presentan un alto índice de morbilidad bucal en todos los indicadores, superiores a estudios nacionales e internacionales. Es prioritario diseñar e implementar programas odontológicos preventivo curativos en este grupo. Estos resultados cuestionan el diseño y posible impacto del nuevo Programa "FONASA Libre Elección 12-17 años" en poblaciones de recursos limitados y con altas necesidades de tratamiento.